Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury

Kidney International

Volumn 81, Issue 9, 2012, Pages 903-918

  Cassis, Paola ^a   Gallon, Lorenzo ^b   Benigni, Ariela ^a   Mister, Marilena ^a   Pezzotta, Anna ^a   Solini, Samantha ^a   Gagliardini, Elena ^a   Cugini, Daniela ^a   Abbate, Mauro ^a   Aiello, Sistiana ^a   Rocchetta, Federica ^a   Scudeletti, Pierangela ^a   Perico, Norberto ^a   Noris, Marina ^a   Remuzzi, Giuseppe ^c  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b NORTHWESTERN UNIVERSITY   (United States)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

anemia; chronic allograft rejection; erythropoietin; transplantation

Indexed keywords

ANGIOGENIC FACTOR; CYCLOSPORIN A; ERYTHROPOIETIN; HEMOGLOBIN; NEPHRIN; PROTEIN BCL 2; WORTMANNIN;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD TRANSFUSION; CELL INFILTRATION; CHRONIC KIDNEY ALLOGRAFT INJURY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; GLOMERULOSCLEROSIS; GLOMERULUS CAPILLARY; HEMOGLOBIN BLOOD LEVEL; INTERSTITIAL NEPHRITIS; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL GRAFT DYSFUNCTION; UPREGULATION;

EID: 84859754845     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.473     Document Type: Article

References (64)

1. Solez K, Colvin RB, Racusen LC et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7: 518-526. (Pubitemid 46376465)
2. Halloran PF, Langone AJ, Helderman JH et al. Assessing long-term nephron loss: is it time to kick the CAN grading system? Am J Transplant 2004; 4: 1729-1730. (Pubitemid 39434427)
3. Joosten SA, Sijpkens YW, van Kooten C et al. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005; 68: 1-13. (Pubitemid 43181359)
4. Shah N, Al-Khoury S, Afzali B et al. Posttransplantation anemia in adult renal allograft recipients: prevalence and predictors. Transplantation 2006; 81: 1112-1118.
5. Molnar MZ, Czira M, Ambrus C et al. Anemia is associated with mortality in kidney-transplanted patients-a prospective cohort study. Am J Transplant 2007; 7: 818-824. (Pubitemid 46481205)
6. Chhabra D, Grafals M, Skaro AI et al. Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol 2007; 3: 1168-1174.
7. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006; 17: 17-25.
8. Norman JT, Orphanides C, Garcia P et al. Hypoxia-induced changes in extracellular matrix metabolism in renal cells. Exp Nephrol 1999; 7: 463-469. (Pubitemid 29517356)
9. Lee SH, Li C, Lim SW et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 2005; 25: 64-76. (Pubitemid 40529278)
10. Bahlmann FH, Song R, Boehm SM et al. Low-dose therapy with the longacting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006-1012. (Pubitemid 39128626)
11. Kasap B, Soylu A, Kuralay F et al. Protective effect of EPO on oxidative renal injury in rats with cyclosporine nephrotoxycity. Pediatr Nephrol 2008; 23: 1991-1999.
12. Roth D, Smith RD, Schulman G et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24: 777-784. (Pubitemid 24350464)
13. Gouva C, Nikolopoulos P, Ioannidis JP et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760. (Pubitemid 38982019)
14. Tapolyai M, Kadomatsu S, Perera-Chong M. R.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline. BMC Nephrol 2003; 4: 3.
15. Druëke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084. (Pubitemid 44749316)
16. Becker BN, Becker YT, Leverson GE et al. Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant 2002; 17: 1667-1673. (Pubitemid 35012172)
17. Ortiz F, Guirado L, D́az J et al. Use of recombinant human erythropoietin in kidney transplant patients with stable graft function. Transplant Proc 2003; 35: 1767-1782.
18. Aufricht C, Marik JL, Ettenger RB. Subcutaneous recombinant human erythropoietin in chronic renal allograft dysfunction. Pediatr Nephrol 1998; 12: 10-13. (Pubitemid 28165771)
19. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31. (Pubitemid 351347536)
20. Eto N, Wada T, Inagi R et al. Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007; 72: 455-463. (Pubitemid 47237606)
21. Logar CM, Brinkkoetter PT, Krofft RD et al. Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007; 72: 489-498. (Pubitemid 47237613)
22. Garcia DL, Anderson S, Rennke HG et al. Anemia lessens and its prevention with recombinant human erytropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 1988; 85: 6142-6146.
23. Lebel M, Rodrigue ME, Agharazii M et al. Anti hypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens 2006; 19: 1286-1292. (Pubitemid 44873189)
24. Torralbo A, Blanco J, Fontanellas A et al. Long-term erythropoietin in rats with reduced renal mass. Nephron 1996; 73: 280-285. (Pubitemid 26159348)
25. Benigni A, Tomasoni S, Turka LA et al. Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. J Am Soc Nephrol 2006; 17: 1665-1672. (Pubitemid 43794669)
26. Perico N, Imberti O, Bontempelli M et al. Toward novel antirejection strategies: in vivo immunosuppressive properties of CTLA4-Ig. Kidney Int 1995; 47: 241-246.
27. Glaser S, Alvaro D, Francis H et al. Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. Am J Physiol Gastrointest Liver Physiol 2005; 290: G813-G826.
28. Blosser CD, Bloom RD. Posttransplant anemia in solid organ recipient. Transplant Rev 2010; 24: 89-98.
29. Noris M, Azzollini N, Pezzotta A et al. Combined treatment with mycophenolate mofetil and an angiotensin II receptor antagonist fully protects from chronic rejection in a rat model of renal allograft. J Am Soc Nephrol 2001; 12: 1937-1946. (Pubitemid 32801370)
30. Albrecht EW, Stegeman CA, Tiebosch AT et al. Expression of inducible and endothelial nitric oxide synthases, formation of peroxynitrite and reactive oxygen species in human chronic renal transplant failure. Am J Transplant 2002; 2: 448-453. (Pubitemid 36306886)
31. MacMillan-Crow LA, Crow JP, Kerby JD et al. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA 1996; 93: 11853-11858. (Pubitemid 26347213)
32. Neto JS, Nakao A, Toyokawa H et al. Low-dose carbon monoxide inhalation prevents development of chronic allograft nephropathy. Am J Physiol Renal Physiol 2006; 290: F324-F334. (Pubitemid 43738984)
33. Urao N, Okigaki M, Yamada H et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 2006; 98: 1405-1413. (Pubitemid 43948065)
34. Kang DH, Joly AH, Oh SW et al. Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 2001; 12: 1434-1447. (Pubitemid 32666326)
35. Shimizu A, Colvin RB, Yamanaka N. Rejection of peritubular capillaries in renal allo-and xeno-graft. Clin Transplant 2000; 14: 6-14.
36. Rosengard BR, Ojikutu CA, Guzzetta PC et al. Induction of specific tolerance to class I-disparate renal allografts in miniature swine with cyclosporine. Transplantation 1992; 54: 490-497.
37. Tanaka T, Hanafusa N, Ingelfinger JR et al. Hypoxia induces apoptosis in SV40-immortalized rat proximal tubular cells through the mitochondrial pathways, devoid of HIF1-mediated upregulation of Bax. Biochem Biophys Res Commun 2003; 309: 222-231. (Pubitemid 36999781)
38. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808-820. (Pubitemid 29100693)
39. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 1995; 47: 740-745.
40. Nitta K, Uchida K, Kimata N et al. Recombinant human erythropoietin stimulates vascular endothelial growth factor release by glomerular endothelial cells. Eur J Pharmacol 1999; 373: 121-124. (Pubitemid 29306717)
41. Hohenstein B, Kuo MC, Addabbo F et al. Enhanced progenitor cell recruitment and andothelial repair after selective endothelial injury of mouse kidney. Am J Physiol Renal Physiol 2010; 298: F1504-F1514.
42. Imamura R, Moriyama T, Isaka Y et al. Erythropoietin protects the kidneys against ischemia reperfusion injury by activating hypoxia inducible factor-1alpha. Transplantation 2007; 83: 1371-1379. (Pubitemid 46800315)
43. Satchell SC, Harper SJ, Tooke JE et al. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 2002; 13: 544-550. (Pubitemid 34106299)
44. Morisada T, Kubota Y, Urano T et al. Angiopoietins and angiopoietin-like proteins in angiogenesis. Endothelium 2006; 13: 71-79. (Pubitemid 44173109)
45. Stein-Oakley AN, Tzanidis A, Fuller PJ et al. Expression and distribution of epidermal growth factor in acute and chronic renal allograft rejection. Kidney Int 1994; 46: 1207-1215. (Pubitemid 24319963)
46. Hotchkiss H, Chu TT, Hancock WW et al. Differential expression of profibrotic and growth factors in chronic allograft nephropathy. Transplantation 2006; 81: 342-349. (Pubitemid 43255717)
47. Vesey DA, Cheung C, Pat B et al. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004; 19: 348-355. (Pubitemid 38195983)
48. Johnson DW, Pat B, Vesey DA et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69: 1806-1813. (Pubitemid 43739209)
49. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-242. (Pubitemid 38886736)
50. Juntilla MM, Koretzky GA. Critical roles of the PI3K/Akt signaling pathway in T cell development. Immunol Lett 2008; 116: 104-110.
51. Kane LP, Weiss A. The PI-3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3. Immunol Rev 2003; 192: 7-20. (Pubitemid 36613319)
52. Jevnikar AM, Mannon RB. Late kidney allograft loss: what we know about it, and what we can do about it. Clin J Am Soc Nephrol 2008; 3: S56-S67.
53. Najafian B, Kasiske BL. Chronic allograft nephropathy. Current Opinion Nephrol Hypertens 2008; 17: 149-155. (Pubitemid 351253039)
54. Bohle A, Mackensen-Haen S, von Gise H et al. The consequences of tubulo-interstitial changes for renal function in glomerulopathies. A morphometric and cytological analysis. Pathol Res Pract 1990; 186: 135-144. (Pubitemid 20097957)
55. Raats CJ, Bakker MA, van den Born J et al. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephrotic syndrome. J Biol Chem 1997; 272: 26734-26741. (Pubitemid 27458901)
56. Susztak K, Raff AC, Schiffer M et al. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233. (Pubitemid 43343319)
57. Pippin J, Kumar V, Stein A et al. The contribution of podocytes to chronic allograft nephropathy. Nephron Exp Nephrol 2009; 111: e1-10.
58. Koshikawa M, Mukoyama M, Mori K et al. Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690-2701.
59. Takano Y, Yamauchi K, Hayakawa K et al. Transcriptional suppression of nephrin in podocytes by macophages. role of inflammatory cytokines and involvement of the PI3K/Akt pathway. FEBS Lett 2007; 581: 421-426. (Pubitemid 46149613)
60. Calo LA, Davis PA, Piccoli A et al. A role for heme oxygenase-1 in the antioxidant and antiapoptotic effects of erythropoietin: the start of a good news/bad news story? Nephron Physiol 2006; 103: 107-111.
61. Heinze G, Kainz A, Hörl WH et al. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. Br Med J 2009; 339: b4018.
62. Corwin HL, Gettinger A, Fabian TC et al. Efficacy and saf ety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965-976. (Pubitemid 47367076)
63. Brines M, Cerami A. Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. J Intern Med 2008; 264: 405-432.
64. Tillmann HC, Kuhn B, Kranzlin B et al. Efficacy and immunogenicity of novel erythropoietic agents and conventional rhEPO in rats with renal insufficiency. Kidney Int 2006; 69: 60-67. (Pubitemid 43117739)